D-Allulose Production: A Comprehensive Review and Update

Allulose formulators, look at the enzyme step first. That is where the latest gains in allulose production are happening. A new review in Foods (DOI: 10.3390/foods13162572) walks through recent progress and updates the landscape. It focuses on enzymatic conversion, not extraction or chemical synthesis.

Why this review matters now

The regulatory door opened wider in the last few years. In 2019, the FDA granted allulose GRAS status. China’s NHC approved it as a new food ingredient. Those approvals let formulators use allulose in more products, and they raised demand. That pushes ingredient makers to find cheaper, more efficient ways to produce it. The review collects those technical advances in one place.

What the review covers

The authors looked at four main areas of enzyme-based production: immobilization, novel enzyme discovery, directed evolution, and metabolic pathway engineering. Immobilization means attaching enzymes to a support so they can be reused. Novel enzyme discovery means hunting for D-allulose 3-epimerases from new organisms. Directed evolution changes enzymes in the lab to make them more stable or active. Metabolic pathway engineering rewires whole cells to produce allulose from cheap substrates.

The review also looks at a multi-enzyme cascade approach. In that system, a cascade of enzymes converts D-fructose into D-allulose directly in juice. The reported conversion rate hit 75%, with a total yield of 60%.

Key findings

One clear theme stands out: no single approach wins everywhere. Each method trades off yield, cost, and process complexity.

Production approach	Main focus in the review
Enzyme immobilization	Reusability and process stability
Novel enzyme discovery	Finding new epimerases with better activity
Directed evolution	Improving enzyme stability and catalytic efficiency
Metabolic pathway engineering	Whole-cell biosynthesis from renewable substrates
Multi-enzyme cascade	High conversion in a single reaction system

The fruit juice cascade result matters for product developers. When you can run biotransformation directly in juice, you avoid a separate sugar purification step. That changes process economics. A 75% conversion from fructose means less leftover fructose to worry about. The 60% overall yield shows some losses exist, but the integrated system still looks promising for lower-sugar beverages.

For manufacturers, the practical message is to evaluate enzymes not just by activity, but by how they fit your downstream process. Free enzymes are simpler to start with. Immobilized enzymes cost more upfront but may cut long-term enzyme costs. Directed evolution has already produced enzyme variants that hold up under industrial conditions, but your substrate stream matters. The review does not recommend a single winner. It gives you a map of options.

Questions formulators ask

Does the review cover regulatory approvals? Yes. It notes the 2019 FDA GRAS recognition and the China NHC approval as a new food ingredient. Both are central to the expansion of allulose use.

What conversion rates can the enzymatic cascade achieve? The cascade converts D-fructose to D-allulose at 75% conversion, with a total yield of 60%. That is one of the stronger numbers in the current literature.

Should I buy enzymes or use a whole-cell system? That depends on your scale and substrate. Whole-cell metabolic engineering suits lower-cost feedstocks. Immobilized purified enzymes suit cleaner reaction streams. The review lays out both, without a universal answer.

Looking ahead

Allulose production is not a commodity process yet. It is still a moving target, and the review captures that movement. For ingredient buyers, the key question is not whether allulose can be made efficiently. It is which enzyme platform will deliver the purity and price your product needs. Watch the cascade work and the new epimerase discoveries. Those are the pieces advancing fastest.